American Journal of Clinical Dermatology

, Volume 19, Issue 2, pp 287–290 | Cite as

American Academy of Dermatology Annual Meeting: San Diego, CA, USA, 16–20 Feb 2018

Meeting Report

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Kathy Fraser is a salaried employee of Adis/Springer and declares no relevant conflicts of interest.

References

  1. 1.
    Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol.  https://doi.org/10.1016/j.jaad.2018.01.017. Accessed 27 Feb 2018 (Epub ahead of print)
  2. 2.
  3. 3.
    Ruzicka T, Hanifin JM, Furue M, et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376(9):826–35.CrossRefPubMedGoogle Scholar
  4. 4.
    Abstract #6753. MOR106, an Anti-IL-17C mAb, a Potential New Approach for Treatment of Moderate-to-severe Atopic Dermatitis: Phase 1 Study. American Academy of Dermatology Annual Meeting, San Diego, CA, USA. 16–20 Feb 2018.Google Scholar
  5. 5.
    Abstract #6658. Proof-of-concept Phase 2a Clinical Trial of ANB020 (anti-IL-33) in the Treatment of Moderate-to-severe Atopic Dermatitis. American Academy of Dermatology Annual Meeting, San Diego, CA, USA. 16–20 Feb 2018.Google Scholar
  6. 6.
    Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175(5):902–11.CrossRefPubMedGoogle Scholar
  7. 7.
    Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015;73(3):395–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Abstract #6533. Primary Results from a Phase 2b, Randomized, Placebo-Controlled Trial of Upadacitinib for Patients with Atopic Dermatitis. American Academy of Dermatology Annual Meeting, San Diego, CA, USA. 16–20 Feb 2018.Google Scholar
  9. 9.
    Abstract # 6684. Patient-reported Outcomes (PROs) from a Phase 2 Double-blinded, Randomized, Multi-center, Placebo-controlled Study of Baricitinib in Adult Patients with Moderate-to-severe Atopic Dermatitis. American Academy of Dermatology Annual Meeting, San Diego, CA, USA. 16–20 Feb 2018.Google Scholar
  10. 10.
    Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2018.  https://doi.org/10.1016/j.jaad.2018.01.018 (Epub ahead of print).Google Scholar
  11. 11.
    Abstract #6777. Efficacy and Safety of Oral ASN002, a Novel JAK/SYK inhibitor, in Patients with Moderate-to-Severe Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Clinical Study. American Academy of Dermatology Annual Meeting, San Diego, CA, USA. 16–20 Feb 2018.Google Scholar
  12. 12.
    Abstract #6495. Efficacy and Safety of Risankizumab: Results from Two Double-blind, Placebo- and Ustekinumab-controlled, Phase 3 Trials in Moderate-to-severe Plaque Psoriasis. American Academy of Dermatology Annual Meeting, San Diego, CA, USA. 16–20 Feb 2018.Google Scholar
  13. 13.
    Abstract 6748. Long-term Efficacy of Guselkumab Treatment After Drug Withdrawal and Retreatment in Patients with Moderate-severe Plaque Psoriasis: Results from VOYAGE 2. American Academy of Dermatology Annual Meeting, San Diego, CA, USA. 16–20 Feb 2018.Google Scholar
  14. 14.
    Abstract # 6696. Dual Neutralization of Interleukin (IL)-17A and IL-17F with Bimekizumab in Moderate-to-severe Psoriasis: Results from a Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study. American Academy of Dermatology Annual Meeting, San Diego, CA, USA. 16–20 Feb 2018.Google Scholar
  15. 15.
    Meylan P, Lang C, Mermoud S, et al. Skin Colonization by Staphylococcus aureus Precedes the Clinical Diagnosis of Atopic Dermatitis in Infancy. J Invest Dermatol. 2017;137(12):2497–504.CrossRefPubMedGoogle Scholar
  16. 16.
    Nakatsuji T, Chen TH, Narala S, et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci Transl Med. 2017.  https://doi.org/10.1126/scitranslmed.aah4680.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97–103.CrossRefPubMedGoogle Scholar
  18. 18.
    Rebello D, Wang E, Yen E, et al. Hair growth in two alopecia patients after fecal microbiota transplant. ACG Case Rep J. 2017;13(4):e107.  https://doi.org/10.14309/crj.2017.107.Google Scholar
  19. 19.
    Drent M, Cremers JP, Jansen TL, Baughman RP. Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):91–107.PubMedGoogle Scholar
  20. 20.
    Pariser RJ, Paul J, Hirano S, et al. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765–73.CrossRefPubMedGoogle Scholar
  21. 21.
    Min MS, Lebwohl M. Treatment of recalcitrant granuloma annulare (GA) with adalimumab: A single-center, observational study. J Am Acad Dermatol. 2016;74(1):127–33.CrossRefPubMedGoogle Scholar
  22. 22.
    Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2):205–17.CrossRefPubMedGoogle Scholar
  23. 23.
    Blok JL, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174(4):839–46.CrossRefPubMedGoogle Scholar
  24. 24.
    Quist SR, Kraas L. Treatment options for pyoderma gangrenosum. J Dtsch Dermatol Ges. 2017;15:34–40.Google Scholar
  25. 25.
    Petrof G, Almaani N, Archer CB, Griffiths WAD, Smith CH. A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists. J Eur Acad Dermatol Venereol. 2013;27:e131–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Chowdhary M, Davila U, Cohen DJ. Ustekinumab as an alternative treatment option for chronic pityriasis rubra pilaris. Case Rep Dermatol. 2015;7(1):46–50.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Zakka LR, Shetty SS, Ahmed AR. Rituximab in the treatment of pemphigus vulgaris. Dermatol Ther (Heidelb). 2012;2(1):17.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Adis PublicationsAucklandNew Zealand

Personalised recommendations